## **REMARKS**

Currently claims 1-13, 17-18, 23-25, 27 and 29 are pending. Applicants amended the claims to remove unintentional duplication, place them in a form appropriate to US practice, and to reduce the filing fee by, *inter alia*, removing multiple dependency. Applicants amend the specification for purposes of adding the priority information. The attached Abstract has been placed on a separate sheet of paper according to US practice.

Respectfully submitted,

Virginia G. Campen Attorney for Applicant Registration No. 37,092

Date: 14 Jan. 2005 GlaxoSmithKline

Corporate Intellectual Property

Five Moore Drive P.O. Box 13398

Research Triangle Park, NC 27709-3398

Phone: 919-483-1012 Facsimile: 919-483-7988